Rats tend to websites where they have received morphine return and locations where they received to avoid a KOR agonists. That is what has occurred in this study, except that the single cocaine exposure significantly increased both their attraction to the places where they. Received morphine and their aversion to the places the the KOR agonists obtained.
The study instead of air conditioning, in which, the animals either an attraction or aversion to two differently colored and textured chambers One group one of the two drugs or placebo, are involved the expression.Such statements are include, among others , statements regarding the provisional results, the clinical development schedules and prospects for Genaera applications including the trodusquemine and to the IL – 9 antibody software. Forward looking statements of these forward-looking statements by the use of words expressed in such statements like identify anticipate , believe , continue , development , expect , plan and potential or in other words of similar meaning. Genaera ‘s actual results and performance may differ in terms from those currently anticipated , and these and other forward-looking statements as the result of a number of risk factors including, but not restricted to: Genaera history of operating losses since launch and their need to on additional funding to operate company, that charges, lags and uncertainties in scientific research, drug development, clinical trials and regulatory permit, a risk that clinical trials for Genaera product candidates are including the trodusquemine delayed and the IL-9 antibody program or not successfully, have the risk that Genaera may not obtain authorization for its product, whether due to of appropriateness development program, the conduct of the clinical trials, these forward several methods of analysis and interpretation of data, regulatory interpretations of of clinical risks and benefits, and do not; Genaera confident of his staff, arising in connection with which developing and marketing Genaera drug candidates, market acceptance Genaera products, if regulatory approval obtained, contest, overall financial, economic, regulatory and political Service , which discusses the biotech and pharmaceutical industry , and other risk and uncertainties presented in this release and in Genaera filings with the U.S.